Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool proprietary data for drug discovery using an AI model. These companies are joining an existing consortium that already includes AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ). The pharmaceutical companies will contribute data from several thousand experimentally de ...

Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is announcing that, further to the Company's press releases of May 16, 2024, June 21, 2024 and July 19, 2024, the Company is formally providing notice that it will be accelerating the expiry date of the warrants issued in relation to its non-brokered private placement unit offering (the "Offering"). The offering res ...

Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to considerable risk.Did you know that if you have a reliable income stock that yields 6%, you would only need to invest about $16,700 in it to collect $1,000 in dividends over the course of a full year? The average stock on the S&P 500, meanwhile, yields just 1.2%, and it would take an investment of more than $83,000 to generate that same level of dividend income.That's a big part of why high- ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. If Big Pharma was a boy’s club before, now it’s even more so. GSK announced this week that CEO Emma Walmsley is stepping down and handing the reins to the company’s chief commercial officer Luke Miels by the end of the year. The shift brings GSK into what Walmsley described as a “pivotal year.” Walmsley, a former executive from L’Oreal, shifted to the drug industry ...

Key Points Pfizer stock offers a yield above 6% at recent prices. MPLX LP is a pipeline operator that offers a yield above 7% at the moment. Pfizer and MPLX LP could continue raising their dividend payouts for many years to come. 10 stocks we like better than Pfizer › Does the government shutdown have you feeling queasy about investing in stocks? It's understandable, but history says your portfolio's going to be just fine. The last government shutdown, in 2019, is hardly noticeable on a chart of ...

The pharma giant just eliminated two big risks.The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's intention to lower drug prices and slap a tariff on pharma imports. These two efforts could weigh significantly on these companies' earnings -- and uncertainty about when and how they would be rolled out prompted investors to think twice about buying shares of drug ...

Ah, the stock market. That bastion of rational exuberance, where every tick reflects a careful calculus of earnings, growth, and geopolitical stability. Or, in the era of Donald J. Trump, a frantic scramble to decipher the latest pronouncement from Truth Social. The past few days, particularly the opening salvo of October 2025, have offered a masterclass in market volatility, policy paradoxes, and the sheer audacity of an administration that treats global trade like a high-stakes game of Monopoly, albeit wi ...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecen ...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecen ...

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and only approved therapy for DMD in Canada Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in ...